Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled aclidinium bromide trial in COPD
2005-005101-39Phase 3Completed
- Sponsor
- Almirall
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Aclidinium bromide 200 µg once daily with Placebo once daily (2 arms). Primary endpoint: Primary bronchodilator efficacy. Started Apr 2006; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-005101-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005101-39.